User profiles for Amriti Lulla
 | Amriti R. LullaMD Anderson Cancer Center Verified email at mdanderson.org Cited by 813 |
[HTML][HTML] Discovery and clinical introduction of first-in-class imipridone ONC201
…, N Madhukar, A Lev, M Baumeister, L Zhou, A Lulla… - Oncotarget, 2016 - ncbi.nlm.nih.gov
ONC201 is the founding member of a novel class of anti-cancer compounds called
imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the …
imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the …
[HTML][HTML] Role of dopamine receptors in the anticancer activity of ONC201
ONC201/TIC10 is a first-in-class small molecule inducer of TRAIL that causes early activation
of the integrated stress response. Its promising safety profile and broad-spectrum efficacy …
of the integrated stress response. Its promising safety profile and broad-spectrum efficacy …
[HTML][HTML] Current treatment of early breast cancer: adjuvant and neoadjuvant therapy
Breast cancer is the most commonly diagnosed cancer in women. The latest world cancer
statistics calculated by the International Agency for Research on Cancer (IARC) revealed that …
statistics calculated by the International Agency for Research on Cancer (IARC) revealed that …
Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212
Anti-cancer small molecule ONC201 upregulates the integrated stress response (ISR) and
acts as a dual inactivator of Akt/ERK, leading to TRAIL gene activation. ONC201 is under …
acts as a dual inactivator of Akt/ERK, leading to TRAIL gene activation. ONC201 is under …
Small-molecule prodigiosin restores p53 tumor suppressor activity in chemoresistant colorectal cancer stem cells via c-Jun-mediated ΔNp73 inhibition and p73 …
Tumor suppressor p53 is frequently mutated or inactivated in colorectal cancer. In contrast,
p53 family member p73 is rarely mutated in colorectal cancer and p73 activation elicits p53-…
p53 family member p73 is rarely mutated in colorectal cancer and p73 activation elicits p53-…
miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells
AR Lulla, MJ Slifker, Y Zhou, A Lev, MB Einarson… - Cancer research, 2017 - AACR
CDK4/6 targeting is a promising therapeutic strategy under development for various tumor
types. In this study, we used computational methods and The Cancer Genome Atlas dataset …
types. In this study, we used computational methods and The Cancer Genome Atlas dataset …
[HTML][HTML] ONC201: a new treatment option being tested clinically for recurrent glioblastoma
Glioblastoma is an aggressive central nervous system tumor with a 5-year-survival rate of
less than 10%. Patients diagnosed with the disease are treated with surgery, radiation and …
less than 10%. Patients diagnosed with the disease are treated with surgery, radiation and …
[HTML][HTML] Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
Cancer stem cells (CSCs) correlate with recurrence, metastasis and poor survival in clinical
studies. Encouraging results from clinical trials of CSC inhibitors have further validated …
studies. Encouraging results from clinical trials of CSC inhibitors have further validated …
[HTML][HTML] Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP
Pancreatic cancer is chemo-resistant and metastasizes early with an overall five-year survival
of∼ 8.2%. First-in-class imipridone ONC201 is a small molecule in clinical trials with anti-…
of∼ 8.2%. First-in-class imipridone ONC201 is a small molecule in clinical trials with anti-…
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies
ONC201, founding member of the imipridone class of small molecules, is currently being
evaluated in advancer cancer clinical trials. We explored single agent and combinatorial …
evaluated in advancer cancer clinical trials. We explored single agent and combinatorial …